This category covers companies developing neurotechnology and neuromodulation devices for Alzheimer's disease (AD) and related neurodegenerative conditions. These technologies include brain-computer interfaces (BCI), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and neuroprosthetics aimed at cognitive enhancement, memory support, and disease modification.
Neurotechnology represents a promising frontier for Alzheimer's treatment, offering non-pharmacological approaches to modulate neural circuits, enhance cognitive function, and potentially slow disease progression. While many of these technologies are still in development, several companies have received FDA breakthrough device designations and are actively conducting clinical trials[@neurotechnology2024].
BCI technology enables direct communication between neural devices and external systems, with emerging applications for Alzheimer's disease including cognitive monitoring, memory enhancement, and neural circuit modulation.
This category covers companies developing neurotechnology and neuromodulation devices for Alzheimer's disease (AD) and related neurodegenerative conditions. These technologies include brain-computer interfaces (BCI), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and neuroprosthetics aimed at cognitive enhancement, memory support, and disease modification.
Neurotechnology represents a promising frontier for Alzheimer's treatment, offering non-pharmacological approaches to modulate neural circuits, enhance cognitive function, and potentially slow disease progression. While many of these technologies are still in development, several companies have received FDA breakthrough device designations and are actively conducting clinical trials[@neurotechnology2024].
BCI technology enables direct communication between neural devices and external systems, with emerging applications for Alzheimer's disease including cognitive monitoring, memory enhancement, and neural circuit modulation.
| Company | Product | Technology | AD Application | Status |
|---------|---------|------------|----------------|--------|
| [Neuralink](/companies/neuralink) | N1 Implant | 1,024+ electrode array | Memory restoration, neural recording | Human trials (PRIME Study) |
| [Synchron](/companies/synchron) | Stentrode | Endovascular stent-array | Motor/cognitive interface | Phase 1 COMMANDER |
| [Blackrock Neurotech](/companies/blackrock-neurotech) | Utah Array | Intracortical microelectrode | Neural prosthetics research | Clinical |
| [Precision Neuroscience](/companies/precision-neuroscience) | Layer 7 Cortical Interface | Surface ECoG array | Epilepsy/cognitive mapping | Phase 1 |
| [Paradromics](/companies/paradromics) | Connexus DDI | High-bandwidth intracortical | Communication restoration | Preclinical |
| Company | Product | Technology | AD Application | Status |
|---------|---------|------------|----------------|--------|
| [EMOTIV](/companies/emotiv) | EPOC+ | 14-channel EEG | Cognitive monitoring | Commercial |
| [g.tec](/companies/gtec) | g.HIamp | 64-256 channel EEG | Research-grade recording | Commercial |
| [BrainCo](/companies/brainco) | Focus | EEG headband | Cognitive training | Commercial |
| [Bitbrain](/companies/bitbrain) | EPOC | EEG wearable | BCI applications | Commercial |
| [Kernel](/companies/kernel) | Flow | Non-invasive hemodynamic | Cognitive enhancement | Development |
DBS uses implanted electrodes to modulate specific brain regions. For Alzheimer's, targets include the fornix, nucleus basalis of Meynert, and entorhinal cortex. Several companies provide DBS systems approved for Parkinson's disease that are being investigated for AD applications.
| Company | Products | AD Research Focus | Status |
|---------|----------|------------------|--------|
| [Medtronic](/companies/medtronic) | Activa PC, RC+S | Fornix stimulation, memory | Investigational |
| [Boston Scientific](/companies/boston-scientific) | Vercise Gevia, Genus | Neural network modulation | Investigational |
| [Abbott](/companies/abbott) | Infinity DBS | Directional stimulation | Research |
| LivaNova | Sentia | DBS system | Research |
TMS uses magnetic fields to stimulate nerve cells in the brain. Several companies provide FDA-approved TMS systems for depression that are being investigated for cognitive enhancement in AD.
| Company | Products | AD Application | Status |
|---------|----------|----------------|--------|
| Nexstim | eXimia NBS | Navigated TMS, cognitive mapping | Research |
| MagVenture | MagPro X100 | rTMS for cognition | Clinical |
| Magstim | Rapid2 | rTMS coil systems | Clinical |
| BrainWay | Deep TMS | Deep brain stimulation | Clinical |
tDCS uses low electrical currents to modulate brain activity. It's being investigated as a non-invasive approach to enhance memory and cognitive function in Alzheimer's patients.
| Company | Products | AD Application | Status |
|---------|----------|----------------|--------|
| Soterix Medical | tDCS | tDCS devices | Investigational |
| Neuroelectrics | Starstim | tDCS/tACS | Research |
| BrainTech | tDCS headset | Cognitive enhancement | Consumer |
Emerging neuroprosthetic technologies aim to restore or enhance memory function in Alzheimer's patients by interfacing directly with neural circuits.
| Company | Technology | Target | Status |
|---------|------------|--------|--------|
| Neuralink | High-density electrode array | Hippocampal prosthesis | Research |
| Various | DARPA's RAM Program | Memory prosthesis | Investigational |
| Karolinska Institute | Neural interface | Memory encoding | Research |
| Company | Technology | Indication | Phase | NCT |
|---------|------------|------------|-------|-----|
| Medtronic | DBS (fornix) | AD/MCI | Phase 1 | NCT03295438 |
| Cognionics/UCSD | Closed-loop neurostimulation | AD | Pilot | NCT02827006 |
| Neuroelectrics | tDCS | AD | Phase 1 | NCT04334538 |
| Company | Funding | Year | Application |
|---------|---------|------|-------------|
| Neuralink | $680M (2024) | BCI, memory restoration |
| Synchron | $100M (2022) | Neural interface |
| Paradromics | $72M (2023) | Communication prosthetics |
| Precision Neuroscience | $93M (2023) | Cortical interface |
The neurotechnology market for Alzheimer's is projected to grow significantly:
| Technology | Invasiveness | Risk | Spatial Resolution | Temporal Resolution | AD Readiness |
|------------|---------------|------|---------------------|----------------------|--------------|
| Intracortical BCI | High | High | Excellent | Excellent | Research |
| DBS | High | Moderate | Good | Excellent | Investigational |
| ECoG | Moderate | Moderate | Good | Excellent | Research |
| TMS | Low | Low | Moderate | Good | Investigational |
| tDCS | Very Low | Very Low | Low | Good | Investigational |
| EEG | None | Minimal | Low | Good | Commercial |
| Target | Technology | Function |
|---------|------------|----------|
| Hippocampus | Invasive BCI, DBS | Memory encoding |
| Entorhinal cortex | Invasive BCI | Memory navigation |
| Nucleus basalis of Meynert | DBS | Cholinergic activation |
| Fornix | DBS | Memory circuits |
| Prefrontal cortex | TMS, tDCS | Cognitive control |
| Company | Institution | Focus |
|---------|-------------|-------|
| Medtronic | University of Pennsylvania | FORESTMEC trial |
| Neuralink | UCSF | Memory research |
| Synchron | Mt. Sinai | Neural interface |
| Boston Scientific | Cleveland Clinic | DBS optimization |